Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Summary

RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have Waldenstrom's macroglobulinemia.

Timeline

Start

1999-12

Primary completion

2002-01

Completion

2005-07

Drugs

Indications